WO2014135834A1 - Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator - Google Patents
Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator Download PDFInfo
- Publication number
- WO2014135834A1 WO2014135834A1 PCT/GB2014/000081 GB2014000081W WO2014135834A1 WO 2014135834 A1 WO2014135834 A1 WO 2014135834A1 GB 2014000081 W GB2014000081 W GB 2014000081W WO 2014135834 A1 WO2014135834 A1 WO 2014135834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- raloxifene
- oxalate
- crystalline
- ethanolate
- sesquihydrate
- Prior art date
Links
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 title claims abstract description 201
- 239000012453 solvate Substances 0.000 title claims abstract description 34
- 150000003839 salts Chemical class 0.000 title claims description 33
- 235000006408 oxalic acid Nutrition 0.000 title description 41
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title description 10
- 239000000333 selective estrogen receptor modulator Substances 0.000 title description 10
- 229960004622 raloxifene Drugs 0.000 claims abstract description 286
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims abstract description 272
- 238000000034 method Methods 0.000 claims abstract description 73
- 230000008569 process Effects 0.000 claims abstract description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 18
- -1 oxalate ethanolate sesqui hydrate Chemical compound 0.000 claims description 56
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 238000006243 chemical reaction Methods 0.000 claims description 30
- 150000004682 monohydrates Chemical class 0.000 claims description 25
- ROCHZUNCIZLTRQ-UHFFFAOYSA-N oxalic acid;propan-2-ol Chemical compound CC(C)O.OC(=O)C(O)=O ROCHZUNCIZLTRQ-UHFFFAOYSA-N 0.000 claims description 25
- 238000004090 dissolution Methods 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 17
- GEVPUGOOGXGPIO-UHFFFAOYSA-N oxalic acid;dihydrate Chemical compound O.O.OC(=O)C(O)=O GEVPUGOOGXGPIO-UHFFFAOYSA-N 0.000 claims description 17
- ZDYUUBIMAGBMPY-UHFFFAOYSA-N oxalic acid;hydrate Chemical compound O.OC(=O)C(O)=O ZDYUUBIMAGBMPY-UHFFFAOYSA-N 0.000 claims description 17
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical group [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 claims description 16
- 229960002119 raloxifene hydrochloride Drugs 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 14
- 208000001132 Osteoporosis Diseases 0.000 claims description 11
- 238000002955 isolation Methods 0.000 claims description 10
- 230000008355 cartilage degradation Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- ANBZWDBEKOZNHY-UHFFFAOYSA-N ethanol;oxalic acid Chemical compound CCO.OC(=O)C(O)=O ANBZWDBEKOZNHY-UHFFFAOYSA-N 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 2
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 17
- 150000004677 hydrates Chemical class 0.000 abstract description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000002360 preparation method Methods 0.000 description 29
- 239000002585 base Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000013078 crystal Substances 0.000 description 15
- 238000002441 X-ray diffraction Methods 0.000 description 13
- 239000012458 free base Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000012738 dissolution medium Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000001069 Raman spectroscopy Methods 0.000 description 4
- 229940011871 estrogen Drugs 0.000 description 4
- 239000000262 estrogen Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000004566 IR spectroscopy Methods 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000010996 solid-state NMR spectroscopy Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000004683 dihydrates Chemical class 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- AMIQFUBBTCOGMI-UHFFFAOYSA-N ethanol oxalic acid hydrate Chemical compound O.C(C)O.C(C(=O)O)(=O)O AMIQFUBBTCOGMI-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 1
- HRSKFUPJAHQBCM-UHFFFAOYSA-N C(C)O.C(C)O.O.O.O Chemical compound C(C)O.C(C)O.O.O.O HRSKFUPJAHQBCM-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- RRQQLORBQGPFOQ-UHFFFAOYSA-N propan-2-ol;sulfuric acid Chemical compound CC(C)O.OS(O)(=O)=O RRQQLORBQGPFOQ-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/56—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention provides novel oxalic acid addition salts and/or solvates of raloxifene, process for their preparation and pharmaceutical compositions thereof.
- SERMs Selective estrogen receptor modulators
- SERMs are a class of compounds that act on the estrogen receptor. A characteristic feature that distinguishes these substances from pure receptor agonists and antagonists is that their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues. SERMs, block the effects of estrogen in the breast tissue. SERMs work by sitting in the estrogen receptors in breast cells. As their name says, SERMs are "selective" - this means that a SERM that blocks estrogen's action in breast cells can activate estrogen's action in other cells, such as bone, liver, and uterine cells. SERMs can be used to treat women both before and after menopause.
- Raloxifene is a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds and it is useful for the prevention and treatment of osteoporosis and beast cancer in postmenopausal women.
- SERM selective estrogen receptor modulator
- Raloxifene is chemically termed as [6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]- [4-[2-(1-piperidyl)ethoxy] phenyl]-methanone and has the structural formula I:
- Raloxifene and its salts can exist in different polymorphic forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
- Raloxifene base was disclosed in US4133814. Other methods of preparing raloxifene base are disclosed in patents such as W09848792 and US4380635.
- US4358593 discloses a process of preparation of raloxifene and its salts.
- WO9609045 discloses non-solvated, crystalline raloxifene hydrochloride characterized by XRD, DSC and IR.
- US20020173645 discloses series of crystalline polymorphic forms of raloxifene hydrochloride namely Form I, Form II, Form III, Form IV and non-solvated crystalline form, characterized by XRD and the processes of preparation thereof.
- WO2004/029046 discloses raloxifene L-laciate hemihydrate, DL-lactate hemihydrate and raloxifene sulphate 2-propanol solvate characterized by XRD and DSC. Processes of their preparation and pharmaceutical compositions containing these compounds is also disclosed in this patent for the treatment of cancer, osteoporosis or for inhibiting cartilage degradation.
- WO2004/029046 describes raloxifene salts such as DL- lactate, L-lactate, succinate, malonate and hydrates thereof.
- EP 584952 describes the use of acid addition salts of raloxifene such as hydrochloride, sulfate, lactate, succinate and malonate for the preparation of pharmaceutical formulations for inhibiting bone degradation and treating or preventing osteoporosis.
- WO2011/0999421 A2 describes raloxifene sulfamates in crystal and amorphous form and hydrates thereof.
- the present invention is directed to inter alia oxalic acid addition salts and/or solvates of raloxifene and/or hydrates of raloxifene, methods of preparing such oxalic acid addition salts and/or solvates/hydrates of raloxifene and methods of treating or preventing osteoporosis and breast cancer in postmenopausal women and for treating cartilage degradation with such oxalic acid addition salts and/or solvates/hydrates of raloxifene.
- pseudopolymorphs include hydrates and/or solvates, more particularly, C1-C4 alcohol solvates, a THF (tetrahydrofuran) solvate and/or hydrated solvates.
- raloxifene oxalate may be in the form of a derivative thereof.
- the derivative may be a pharmaceutically acceptable solvate, hydrate, ester, tautomer, anhydrate, complex, polymorph, prodrug or combination thereof.
- the raloxifene oxalate may be a solvate.
- the raloxifene oxalate solvate is optionally in hydrated form.
- the raloxifene oxalate is a raloxifene oxalate solvate hydrate.
- the solvent that forms the solvate may be a C1-C4 alcoholate, for example methanol, ethanol, n-propanol, i-propanol, n-butanol, 2-n-butanol and i-butanol.
- the solvent is ethanol and the raloxifene oxalate is raloxifene oxalate ethanolate optionally in hydrated form.
- the ethanolate is in hydrated form.
- the hydrate of raloxifene oxalate ethanolate is a sesquihydrate.
- the inventors have discovered a suprisingly advantageous polymorphic form of raloxifene oxalate which is crystalline Form I raloxifene oxalate ethanolate sesquihydrate. This form is described in more detail herein.
- the present invention provides crystalline raloxifene oxalate ethanolate sesquihydrate wherein the said ethanolate sesquihydrate is referred to as Form I.
- the crystalline raloxifene oxalate ethanolate sesquihydrate is relatively stable towards moisture and humidity, thereby representing a crystalline form of raloxifene, thus enhancing the efficacy of the parent molecule in lower doses.
- the crystalline raloxifene oxalate ethanolate sesquihydrate according to the present invention may be characterized by powder X-ray diffraction.
- Crystalline Form I raloxifene oxalate ethanolate sequihydrate may be characterized by having an XRPD diffractogram comprising peaks at 8.59, 9.03,14.22, 17.16, 23.26 and 24.74 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may comprise further peaks at 10.05, 16.17, 19.23, 21.60, 24.08, 25.22, 26.60 and 27.32 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may comprise still further peaks at 1 1.37, 12.75, 15.47 and 20.13 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may be as depicted in Figure 1.
- Crystalline Form I raloxifene oxalate ethanolate sesquihydrate may be characterized by having an intrinsic dissolution profile as shown in Figure 2.
- a process for preparing crystalline raloxifene oxalate ethanolate sesquihydrate comprising forming a solution of raloxifene base and oxalic acid di hydrate in ethanol at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature.
- the raloxifene, as free base may be in any polymorphic form or in a mixture of any polymorphic forms.
- the present invention provides a process for preparing crystalline Form I raloxifene oxalate ethanolate sesquihydrate as defined above and in the claims, the process comprising dissolving raloxifene base in ethanol at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in ethanol to form a reaction mass, and isolating crystalline Form I.
- the oxalic acid is typically added at a temperature ranging from 40°C to 60°C, preferably at a temperature ranging from 50°C to 55°C.
- the oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1.5 hours, more preferably for a time of around 50 minutes to 1 hour 0 minutes, for example over a period of around 60 minutes.
- the isolation may comprise isolating precipitated Form I from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30°C to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours.
- the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
- the process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid. Suitably, the stirring takes place for at least 7 hours, for example around 8 hours.
- the raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide.
- the other salt may be raloxifene hydrochloride.
- crystalline raloxifene oxalate ethanolate sesquihydrate Form I prepared by a process according to the process described above. The process produces crystalline raloxifene oxalate ethanolate sesquihydrate in high yield and purity.
- the derivate of raloxifene oxalate may be a non-solvated hydrate of raloxifene oxalate.
- the hydrate is a hemihydrate.
- the inventors have discovered a surprisingly advantageous polymorphic form of raloxifene oxalate which is crystalline Form II raloxifene oxalate monohydrate. This form is described in more detail herein.
- crystalline raloxifene oxalate monohydrate wherein the said crystal form of this embodiment is referred to as Form II.
- the crystalline raloxifene oxalate monohydrate Form II according to the present invention may be characterized by powder X-ray difractogram.
- Crystalline raloxifene oxalate monohydrate Form II may be characterized by having an XRPD diffractogram comprising peaks at 14.94, 18.60 and 20.34 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may comprise further peaks at 20.04, 21.90 and 22.72 ⁇ 0.2 "2 ⁇ .
- the XRPD diffractogram may comprise still further peaks at 7.00, 10.00 and 16.12 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may be as depicted in Figure 3.
- a process for preparing crystalline raloxifene oxalate monohydrate comprising forming a solution of raloxifene base and oxalic acid dihydrate in methanol solvent at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature.
- the present invention provides a process for preparing crystalline raloxifene oxalate monohydrate Form II as defined herein and in the claims, the process comprising dissolving raloxifene base in methanol at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in methanol to form a reaction mass, and isolating crystalline Form II.
- the oxalic acid is typically added at a temperature ranging from 40° C to 60°C, preferably at a temperature ranging from 50°C to 55°C.
- the oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1.5 hours, more preferably for a time of around 50 minutes to 1 hour 10 minutes, for example over a period of around 60 minutes.
- the isolation may comprise isolating precipitated Form II from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30 C C to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours.
- the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
- the process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid.
- the stirring takes place for at least 7 hours, for example around 8 hours.
- the raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide.
- the other salt may be raloxifene hydrochloride.
- the raloxifene, as free base may be, in any polymorphic form or in a mixture of any polymorphic forms.
- crystalline raloxifene oxalate monohydrate Form II prepared by a process according to the process described above. The process produces crystalline raloxifene oxalate Form II in high yield and purity.
- crystalline raloxifene oxalate isopropanolate hemihydrate wherein the said crystal form of this embodiment is referred to as Form III.
- the crystalline raloxifene oxalate isopropanolate hemihydrate Form III may be characterized by powder X-ray diffractogram. Crystalline raloxifene oxalate isopropanolate hemihydrate Form III may be characterized by having an XRPD diffractogram comprising a peak at 21.38 ⁇ 0.2 °2 ⁇ . The XRPD diffractogram may comprise further peaks at 15.64, 18.69, 19.42, 23.16, 24.18 and 26. 0 ⁇ 0.2 °2 ⁇ . The XRPD diffractogram may comprise still further peaks at 11.90 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may be as depicted in Figure 4.
- a process for preparing crystalline raloxifene oxalate isopropanolate hemihydrate Form III comprising forming a solution of raloxifene base and oxalic acid dihydrate in isopropanol solvent at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature.
- the raloxifene, as free base, may be in any polymorphic form or in a mixture of any polymorphic forms. More particularly, the present invention provides a process for preparing crystalline raloxifene oxalate isopropanolate hemihydrate Form III as defined herein and in the claims, the process comprising dissolving raloxifene base in isopropanol at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in isopropanol to form a reaction mass, and isolating crystalline Form III.
- the oxalic acid is typically added at a temperature ranging from 40°C to 60°C, preferably at a temperature ranging from 50°C to 55°C.
- the oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1 .5 hours, mere preferably for a time of around 50 minutes to 1 hour 10 minutes, for example over a period of around 60 minutes.
- the isolation may comprise isolating precipitated Form III from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30°C to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours.
- the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
- the process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid.
- the stirring takes place for at least 7 hours, for example around 8 hours.
- the raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide.
- the other salt may be raloxifene hydrochloride.
- crystalline raloxifene oxalate isopropanolate hemihydrate Form III prepared by a process according to the process described above.
- crystalline raloxifene oxalate isopropanolate hemihydrate Form III in high yield and purity.
- crystalline raloxifene oxalate THF (tetrahydrofuran) hemisolvate monohydrate wherein the said crystal form of this embodiment is referred to as Form IV.
- the crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV according to the present invention may be characterized by powder X-ray difractogram.
- Crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV may be characterized by having an XRPD diffractogram comprising peaks at 18.48, 19.46 and 21.2 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may comprise further peaks at 10.79, 11.54, 12.02, 16.66, 17.43, 19.80, 24.30 and 24.58 ⁇ 0.2 °2 ⁇ .
- the XRPD diffractogram may be as depicted in Figure 5.
- a process for preparing crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV comprising forming a solution of raloxifene base and oxalic acid dihydrate, in THF solvent at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature.
- the raloxifene, as free base, may be in any polymorphic form or in a mixture of any polymorphic forms.
- the present invention provides a process for preparing crystalline raloxifene oxalate THF hemisolvate monchydrate Form IV as defined above and in the claims, the process comprising dissolving raloxifene base in THF at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in THF to form a reaction mass, and isolating crystalline Form IV.
- the oxalic acid is typically added at a temperature ranging from 40°C to 60°C, preferably at a temperature ranging from 50°C to 55°C.
- the oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1.5 hours, more preferably for a time of around 50 minutes to 1 hour 10 minutes, for example over a period of around 60 minutes.
- the isolation may comprise isolating precipitated Form IV from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30°C to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours.
- the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
- the process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid.
- the stirring takes place for at least 7 hours, for example around 8 hours.
- the raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide.
- the other salt may be raloxifene hydrochloride.
- crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV prepared by a process according to the process described above. The process produces crystalline raloxifene oxalate THF solvate Form IV in high yield and purity.
- the oxalic acid being in the form of a dihydrate provides the water for hydration.
- a pharmaceutical composition comprising raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, Crystalline Form II of raloxifene oxalate monohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate), together with one or more pharmaceutically acceptable excipients, including pharmaceutically acceptable carriers.
- the pharmaceutical composition is in the form of a tablet suitable for oral delivery.
- raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, Crystalline Form II of raloxifene oxalate monohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate) for use in medicine.
- the raloxifene oxalate is for use in treating osteoporosis (particularly in postmenopausal women), breast cancer (particularly in postmenopausal women) and/or cartilage degradation.
- raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesqui hydrate, Crystalline Form II of raloxifene oxalate mortohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate) for use in the manufacture of a medicament for treating or preventing osteoporosis (particularly in postmenopausal women), breast cancer (particularly in postmenopausal women) and/or cartilage degradation.
- a method of treating or preventing osteoporosis comprising administering to a patient in need thereof a therapeutically effective amount of raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, Crystalline Form II of raloxifene oxalate monohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate).
- Figure 2 is the Intrinsic Dissolution Rate for crystalline raloxifene oxalate ethanolate sesquihydrate Form I compared with raloxifene hydrochloride
- Figure 3 is X-ray powder diffraction spectrum of crystalline raloxifene oxalate monohydrate Form II.
- Figure 4 is X-ray powder diffraction spectrum of crystalline raloxifene oxalate isopropanolate hemihydrate Form III.
- Figure 5 is X-ray powder diffraction spectrum of crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV. Detailed Description Of The Invention
- solvated is understood to mean formation of a complex of variable stoichiometry comprising raloxifene of Formula (I) and a solvent.
- solvents for the purpose of the invention may not interfere with the biological activity of the solute.
- the solvent used is a pharmaceutically acceptable solvent.
- suitable pharmaceutically acceptable solvents include C1-C4 alcohol solvents and tetrahydrofuran (THF), and solvates other than water at levels of more than 1%.
- the solvate can be isolated either as an amorphous form or in a crystalline form, preferably in crystalline form.
- the solvate can be further isolated either in anhydrous form or hydrated form.
- hydrate is understood as a substance that is formed by adding water molecules.
- the skilled person will appreciate that the water molecules are absorbed, adsorbed or contained within a crystal lattice of the solid compounds, usually in defined stoichiometric ratio.
- the notation for a hydrated compound may be .nH 2 0, where n is the number of water molecules per formula unit of the compound. For example, in a hemihydrate, n is 0.5; in a monohydrate n is one; in a sesquihydrate, n is 1.5; in a dihydrate, n is 2; and so on.
- the term "substantially the same X-ray powder diffraction pattern" is understood to mean that those X-ray powder diffraction patterns having diffraction peaks with 2 ⁇ values within ⁇ 0.2° of the diffraction pattern referred to herein are within the scope of the referred to diffraction pattern.
- the present invention provides the oxalic acid addition salt of raloxifene.
- the oxalate may be isolated in pseudopolymorphic form as a solvate optionally in hydrated form, or as a non-hydrated solvate.
- pseudopolymorphs provided include solvates, more in particular, a THF solvate, or a C1-C4 alcohol solvate, optionally in hydrated form.
- oxalic acid has two acid groups per molecule
- compounds of these acids and raloxifene may be isolated as either mono- or di-acid addition salts and/or solvates thereof having either one or two raloxifene molecules per acid molecule respectively.
- the ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
- the polymorphs of the present invention have been characterized by powder X-ray diffraction spectroscopy which produces a fingerprint of the particular crystalline form. Measurements of 2 ⁇ values are accurate to within ⁇ 0.2 degrees. All the powder diffraction patterns were measured on a Rigaku Dmax 2200 advanced X-ray powder diffractometer with a copper- ⁇ - ⁇ radiation source.
- the invention further provides processes for the preparation of polymorphs.
- the present invention provides the crystalline raloxifene oxalate ethanolate hydrate.
- raloxifene oxalate ethanolate referred in this specification includes various degrees of hydrates.
- the hydrate is sesquihydrate.
- the acid addition salt and/or solvates thereof according to the invention is raloxifene oxalate ethanolate hydrate
- the acid addition salt is crystalline raloxifene oxalate ethanolate sesquihydrate which is herein and in the claims designated as Form I which is substantially non-hygroscopic and has good flow characteristics.
- the present invention provides a process for preparing the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate in high yield and purity.
- the present invention also provides pharmaceutical compositions comprising the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate.
- the ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
- the ethanol content in raloxifene oxalate may vary in ratio depending on the conditions applied.
- the ratio of raloxifene to the ethanol may range between 2.5wt% (0.5 moles) to 5.0wt% (1.0 mole).
- the raloxifene oxalate comprising 0.5 molecules of ethanol per molecule of raloxifene and about 1 molecule of ethanol per molecule of raloxifene represent the lower and upper ranges respectively
- ethanol content of the crystal form may vary within this range depending on the temperature of the crystal form.
- raloxifene oxalate forms a crystalline sesquihydrate with ethanol wherein the molar ratio of raloxifene to oxalic acid to water is approximately 2:1 :1.5 whereas ethanol is present in the non-stoichiometric ratio ranging from 2.5% (0.5 moles) to 5.0% (1.0 mole).
- the present invention provides crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, methods of preparing the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate in high purity and high yield and pharmaceutical compositions comprising them.
- the advantages of the process include simplicity, eco-friendliness and suitability for commercial use.
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate thereof according to the invention has dissolution properties in dilute hydrochloric acid that secure a high bioavailability of the compound.
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate according to the invention has higher intrinsic dissolution rates in dilute hydrochloric acid compared with free raloxifene.
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate has an XRD pattern with characteristics peaks at 8.59, 9.03 and 14.22 ⁇ 0.2 °2 ⁇ .
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate may have an XRD pattern with characteristics peaks at 8.59, 9.03, 14.22, 17.16, 23.26 and 24.74 ⁇ 0.2 °2 ⁇ .
- the XRD pattern may have further peaks at 10.05, 16.17, 19.23, 21.60, 24.08, 25.22, 26.60 and 27.32 ⁇ 0.2 °2 ⁇ .
- the XRD pattern may have still further peaks at 1 1.37, 12.75, 15.47 and 20.13 ⁇ 0.2 °2 ⁇ .
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate has an XRPD pattern with those peaks at °2 ⁇ values ⁇ 0.2 °2 ⁇ as depicted in Table 1.
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate has substantially the same XRPD pattern with peaks at 2 ⁇ values as depicted in Table 1.
- Table 1 Table of values for the XRPD pattern depicted in Figure 1
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate of the present invention is characterized by having an intrinsic dissolution profile as shown in Figure 2.
- samples were measured to compare the influence of the different parameter settings.
- an automated sample collector removes aliquots from dissolution medium for analysis. The time interval for sampling can vary, for example, from 2 to 30 minutes, depending on the properties of the drug and dissolution medium used. Suitable dissolution equipment for these operations includes LAB INDIA DISSO 2000.
- Form I may be further characterized by other methods including, but not limited to IR, solid state NMR and Raman spectroscopy.
- a process for the preparation of the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate may comprise: dissolving raloxifene base in ethanol at 40-60°C, adding a solution of oxalic acid dihydrate in ethanol, stirring for at least 5 hours, isolating the precipitated crystalline Form I of raloxifene oxalate ethanolate sesquihydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hrs.
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate may be prepared by a process comprising; converting any acid addition salt of raloxifene into the free base and subsequently converting free base into the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate.
- raloxifene acid addition salt used in the preparation of the Form I may be in any polymorphic form or in a mixture of any polymorphic forms wherein the said raloxifene in hydrated, solvated, non-solvated or mixture of hydrated, solvated or non-solvated forms thereof.
- raloxifene is provided in the form of raloxifene hydrochloride.
- raloxifene hydrochloride used for the above process, as well as for the following processes, describe in this application can be obtained by any method known to a skilled artisan.
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate obtained according to the present invention is substantially free from other forms of raloxifene.
- substantially free from other forms of raloxifene shall be understood to mean that the polymorphs of raloxifene contain less than 10%, preferably less than 5%, of any other forms of raloxifene and less than 1 % of other impurities or solvates.
- the process of invention may be used as a method for purifying any form of raloxifene, as well as for the preparation of the new polymorphic forms.
- Yet another aspect of the present invention provides a novel polymorphic form of raloxifene oxalate monohydrate which is hereinafter designated as Form II which is substantially non-hygroscopic and has good flow characteristics.
- the ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
- raloxifene oxalate forms a crystalline monohydrate with water wherein the molar ratio of raloxifene to oxalic acid to water is approximately 2:1:1.
- the present invention provides a process for preparing the novel Form II of raloxifene oxalate monohydrate in high yield and purity.
- the present invention also provides pharmaceutical compositions comprising Form II of raloxifene oxalate monohydrate.
- the crystalline polymorph Form II of raloxifene oxalate monohydrate has an XRD pattern with characteristics peaks at 14.94, 18.60 and 20.34 ⁇ 0.2 °2 ⁇ .
- the XRD pattern may be further characterized by an XRD with peaks at 20.04, 21.90 and 22.72 ⁇ 0.2 °2 ⁇ .
- the XRD pattern comprises still further peaks at 7.00, 10.00 and 16.12 ⁇ 0.2 "2 ⁇ .
- the crystalline polymorph Form II of raloxifene oxalate monohydrate has substantially the same XRPD pattern with peaks at 2 ⁇ values as depicted in Table 2.
- Table 2 Table of values for the XRPD pattern depicted in Figure 3
- the crystalline polymorph Form II of raloxifene oxalate monohydrate has substantially the same XRPD pattern with peaks at 2 ⁇ values as depicted in Figure 3.
- Form II may be characterized by other methods including but not limited to IR, solic " state NMR and Raman spectroscopy.
- a process for the preparation of crystalline Form II of raloxifene oxalate monohydrate may comprise the steps of: dissolving raloxifene base in methanol at 55-60°C, adding a solution of oxalic acid dihydrate in methanol, stirring for at least 8 hours, isolating the precipitated crystalline Form II of raloxifene oxalate monohydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hrs.
- the present invention further provides a novel polymorph form of raloxifene oxalate isopropanolate hemihydrate which is hereinafter designated as Form III which is substantially non-hygroscopic and has good flow characteristics.
- the ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
- raloxifene oxalate forms a crystalline hemihydrate with isopropanol wherein the molar ratio of raloxifene to oxalic acid to IPA to water is approximately 2:1 :2:0.5.
- the present invention provides a process for preparing the novel Form III of raloxifene oxalate isopropanolate hemihydrate in high yield and purity.
- the present invention also provides pharmaceutical compositions comprising Form III of raloxifene oxalate isopropanolate hemihydrate.
- the crystalline polymorph Form III of raloxifene oxalate isopropanolate hemihydrate has an XRD pattern with a characteristic peak at 2 .38 ⁇ 0.2 "2 ⁇ .
- the XRD pattern may be further characterized by an XRD with peaks at 15.64, 18.69, 19.42, 23.16, 24.18 and 26.10 ⁇ 0.2 °2 ⁇ .
- the XRD pattern comprises a still further peak at 1 1.90 ⁇ 0.2 °2 ⁇ .
- the crystalline polymorph Form III of raloxifene oxalate isopropanolate hemihydrate has substantially the same XRPD pattern with peaks at 2 ⁇ values as depicted in Table 3.
- Table 3 Table of values for the XRPD pattern depicted in Figure 4
- the crystalline polymorph Form III of raloxifene oxalate isopropanolate hemihydrate has substantially the same XRPD pattern with peaks at 2 ⁇ values as depicted in Figure 4.
- Form III may be characterized by other methods including but not limited to IR, solid state NMR and Raman spectroscopy. According to another aspect of the present invention there is provided a process for the preparation of crystalline Form III of raloxifene oxalate isopropanolate hemihydrate.
- the process may comprise the steps of dissolving raloxifene base in isopropanol at 55-60°C, adding a solution of oxalic acid dihydrate in isopropanol, stirring for at least 8 hours, isolating the precipitated crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hrs.
- Yet another aspect of the present invention provides a novel polymorphic form of raloxifene oxalate THF hemisolvate monohydrate which is hereinafter designated as Form IV which is substantially non-hygroscopic and has good flow characteristics.
- the ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
- raloxifene oxalate forms a crystalline hemisolvate with THF wherein the molar ratio of raloxifene to oxalic acid to THF to water is approximately 2:1 :0.5:1.
- the present invention provides a process for preparing the novel Form IV of raloxifene oxalate THF hemisolvate monohydrate in high yield and purity.
- the present invention also provides pharmaceutical compositions comprising Form IV of raloxifene oxalate THF hemisolvate monohydrate.
- the crystalline polymorph Form IV of raloxifene oxalate THF hemisolvate monohydrate has an XRD pattern with characteristics peaks at 18.48, 19.46 and 21.2 ⁇ 0.2 °2 ⁇ .
- the XRD pattern may be further characterized by an XRD with peaks at 10.79, 11.54, 12.02, 16.66, 17.43, 19.80, 24.30 and 24.58 ⁇ 0.2 °2 ⁇ .
- the XRD pattern comprises still further peaks at 20.62 and 25.64 ⁇ 0.2 °2 ⁇ .
- the crystalline polymorph Form IV of raloxifene oxalate THF hemisolvate monohydrate has substantially the same XRPD pattern with peaks at 2 ⁇ values as depicted in Table 4.
- Table 4 Table of values for the XRPD pattern depicted in Figure 5
- the crystalline polymorph Form IV of raloxifene oxalate THF hemisolvate monohydrate has substantially the same XRPD pattern with peaks at 2 ⁇ values as depicted in Figure 5.
- Form IV may be characterized by other methods including but not limited to IR, solid state NMR and Raman spectroscopy.
- a process for the preparation of crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate may comprise the steps of: dissolving raloxifene base in THF at 55-60°C, adding a solution of oxalic acid dihydrate in THF, stirring for at least 8 hours, isolating the precipitated crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hours.
- the process of invention may be used as a method for purifying any form of raloxifene oxalate, as well as for the preparation of the new polymorphic forms.
- a pharmaceutical composition comprising polymorphic forms of raloxifene oxalate as described above, together with one or more pharmaceutically acceptable excipients.
- the raloxifene oxalate used in the preparation of pharmaceutical compositions may substantially consist of one of forms I, II, III or IV described above, or may substantially consist of a combination of two or more of said forms.
- polymorphic Forms of raloxifene oxalate as described above, in the preparation of a medicament useful in treating or preventing osteoporosis and breast cancer in postmenopausal women and for treating cartilage degradation.
- Raloxifene HCI 200 gm was stirred with methanol (2000 ml) at room temperature. An aqueous solution of sodium hydroxide (50 gm dissolved in 200 ml of water) was added, stirred and cooled to 15°C - 20°C. The pH of the reaction mass was adjusted to 8.0 to 8.5 using 20% aqueous HCI solution. The temperature of the reaction mass was raised to 25°C - 30°C and stirred for 12 hours. To the reaction mass was added water (4000 ml) and the pH was adjusted to 8.0 - 8.5 using 10% aqueous NaOH solution and stirred for 30 minutes.
- Raloxifene Base 180 gm was dissolved in ethanol (1800 ml) at 50°C-55 C C.
- a solution of oxalic acid dihydrate 23.01 gm in 460 ml of ethanol was added slowly at 50°C-55°C over a period of 60 minutes and stirred for 8 hours.
- the reaction mass cooled to 25°C - 30°C, stirred for 30 minutes.
- the solid was isolated by filtration, washed with ethanol (100 ml) and dried under vacuum at 75°C - 85°C for 8 hours to yield 190 gm of titled compound.
- a tableting mixture (50 mg) comprising solely crystalline Form I of raloxifene oxalate ethanolate sesquihydrate prepared according to the example 1 (i.e. with no excipients), was prepared and compressed to a pellet using a manual hand press operating at a compression pressure of 1 ton for 1 minute.
- the pellet was fixed in a PFTE holder, such that only the pellet surface came into contact with the dissolution medium.
- the PFTE loaded holder was placed in the dissolution vessel containing 900 ml of 2% SLS (sodium lauryl sulphate) in water at 35°C - 40°C. Two pellets were measured for each run of the design of the experiments. Stirring was performed with a paddle rotating at 100 rpm. The dissolution was followed up to 1440 min and the concentration of active ingredient, raloxifene, dissolved in the test medium was determined by removing samples of 10 ml at the specified time intervals.
- the concentration of crystalline Form I of raloxifene oxalate ethanolate sesquihydrate was quantified by UV method at a maximum wavelength of 280 nm under the conditions as specified below:
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate exhibited a superior rate of dissolution as shown in Table 2.
- the peak dissolution of 82.0 % was achieved at 1080 min for the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate; whereas, at the same time, 62.0 % was achieved for raloxifene hydrochloride.
- another aspect of the present invention is crystalline Form I of raloxifene oxalate ethanolate sesquihydrate characterised by a peak dissolution (typically when measured at a temperature ranging from 35°C to 40°C) of at least around 75%, preferably at least around 79%, more preferably at least around 81%, particularly when dissolution is measured in accordance with the above procedure.
- the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate is characterised when in the form of a compressed tablet.
- Raloxifene Base (10 gm) was dissolved in methanol (100 ml) at 50°C - 55°C. A solution of oxalic acid dihydrate (1.27 gm in 25 ml of methanol) was added slowly at 50°C - 55°C over a period of 60 minutes and stirred for 8 hours. The reaction mass cooled to 25°C - 30°C, stirred for 30 minutes. The solid was isolated by filtration, washed with methanol (10 ml) and dried under vacuum at 75°C -85°C for 8 hours to yield 9.0 gm of titled compound.
- Raloxifene Base (10 gm) was dissolved in THF (100 ml) at 50°C - 55°C. A solution of oxalic acid dihydrate (1.27 gm in 25 ml of THF) was added slowly at 50°C - 55°C over a period of 60 minutes and stirred for 8 hours. The reaction mass cooled to 25°C - 30°C, stirred for 30 minutes. The solid was isolated by filtration, washed with THF (10 ml) and dried under vacuum at 75°C -85°C for 8 hours to yield 9.7 gm of titled compound. It will be appreciated that the invention may be modified within the scope of the appended claims.
Abstract
The present invention provides raloxifene oxalate, including derivatives thereof. In particular, the present invention provides solvates and/or hydrates of raloxifene oxalate, and polymorphs thereof. The present invention also provides processes for preparing the novel compounds, pharmaceutical compositions including the novel compounds and medical uses of the novel compounds.
Description
OXALIC ACID ADDITION SALTS AND/OR SOLVATES OF A SELECTIVE ESTROGEN
RECEPTOR MODULATOR
Technical Field of the Invention
The present invention provides novel oxalic acid addition salts and/or solvates of raloxifene, process for their preparation and pharmaceutical compositions thereof.
Background of the Invention
Selective estrogen receptor modulators (SERMs) are a class of compounds that act on the estrogen receptor. A characteristic feature that distinguishes these substances from pure receptor agonists and antagonists is that their action is different in various tissues, thereby granting the possibility to selectively inhibit or stimulate estrogen-like action in various tissues. SERMs, block the effects of estrogen in the breast tissue. SERMs work by sitting in the estrogen receptors in breast cells. As their name says, SERMs are "selective" - this means that a SERM that blocks estrogen's action in breast cells can activate estrogen's action in other cells, such as bone, liver, and uterine cells. SERMs can be used to treat women both before and after menopause.
Raloxifene is a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds and it is useful for the prevention and treatment of osteoporosis and beast cancer in postmenopausal women. Raloxifene is chemically termed as [6-hydroxy-2-(4-hydroxyphenyl)-benzothiophen-3-yl]- [4-[2-(1-piperidyl)ethoxy] phenyl]-methanone and has the structural formula I:
Raloxifene and its salts can exist in different polymorphic forms, which may differ from each other in terms of stability, physical properties, spectral data and methods of preparation.
Raloxifene base was disclosed in US4133814. Other methods of preparing raloxifene base are disclosed in patents such as W09848792 and US4380635.
US4358593 discloses a process of preparation of raloxifene and its salts. WO9609045 discloses non-solvated, crystalline raloxifene hydrochloride characterized by XRD, DSC and IR. US20020173645 discloses series of crystalline polymorphic forms of raloxifene hydrochloride namely Form I, Form II, Form III, Form IV and non-solvated crystalline form, characterized by XRD and the processes of preparation thereof.
WO2004/029046 discloses raloxifene L-laciate hemihydrate, DL-lactate hemihydrate and raloxifene sulphate 2-propanol solvate characterized by XRD and DSC. Processes of their preparation and pharmaceutical compositions containing these compounds is also disclosed in this patent for the treatment of cancer, osteoporosis or for inhibiting cartilage degradation. WO2004/029046 describes raloxifene salts such as DL- lactate, L-lactate, succinate, malonate and hydrates thereof.
EP 584952 describes the use of acid addition salts of raloxifene such as hydrochloride, sulfate, lactate, succinate and malonate for the preparation of pharmaceutical formulations for inhibiting bone degradation and treating or preventing osteoporosis. WO2011/0999421 A2 describes raloxifene sulfamates in crystal and amorphous form and hydrates thereof.
One important property associated with solid state forms of drug substances is their aqueous solubility. Compounds having poor water solubility can lead to limited oral bioavailability when administered in patients.
Consequently, it would be a significant contribution to the art to provide new forms of raloxifene; having increased solubility, and methods of preparation, pharmaceutical formulations, and methods of use thereof.
Summary of the invention
The present invention is directed to inter alia oxalic acid addition salts and/or solvates of raloxifene and/or hydrates of raloxifene, methods of preparing such oxalic acid addition salts and/or solvates/hydrates of raloxifene and methods of treating or preventing osteoporosis and breast cancer in postmenopausal women and for treating cartilage degradation with such oxalic acid addition salts and/or solvates/hydrates of raloxifene.
The oxalic acid addition salts and/or solvates/hydrates of raloxifene may be in a pseudopolymorphic form. Accordingly, pseudopolymorphs provided include hydrates and/or solvates, more particularly, C1-C4 alcohol solvates, a THF (tetrahydrofuran) solvate and/or hydrated solvates.
According to one aspect of the present invention, there is provided raloxifene oxalate. The raloxifene oxalate may be in the form of a derivative thereof. The derivative may be a
pharmaceutically acceptable solvate, hydrate, ester, tautomer, anhydrate, complex, polymorph, prodrug or combination thereof.
The raloxifene oxalate may be a solvate. The raloxifene oxalate solvate is optionally in hydrated form. Suitably, the raloxifene oxalate is a raloxifene oxalate solvate hydrate. The solvent that forms the solvate may be a C1-C4 alcoholate, for example methanol, ethanol, n-propanol, i-propanol, n-butanol, 2-n-butanol and i-butanol. Preferably, the solvent is ethanol and the raloxifene oxalate is raloxifene oxalate ethanolate optionally in hydrated form. Preferably the ethanolate is in hydrated form. Suitably, the hydrate of raloxifene oxalate ethanolate is a sesquihydrate. The inventors have discovered a suprisingly advantageous polymorphic form of raloxifene oxalate which is crystalline Form I raloxifene oxalate ethanolate sesquihydrate. This form is described in more detail herein.
Thus, the present invention provides crystalline raloxifene oxalate ethanolate sesquihydrate wherein the said ethanolate sesquihydrate is referred to as Form I.
The crystalline raloxifene oxalate ethanolate sesquihydrate is relatively stable towards moisture and humidity, thereby representing a crystalline form of raloxifene, thus enhancing the efficacy of the parent molecule in lower doses.
The crystalline raloxifene oxalate ethanolate sesquihydrate according to the present invention may be characterized by powder X-ray diffraction.
Crystalline Form I raloxifene oxalate ethanolate sequihydrate may be characterized by having an XRPD diffractogram comprising peaks at 8.59, 9.03,14.22, 17.16, 23.26 and 24.74 ± 0.2 °2Θ. The XRPD diffractogram may comprise further peaks at 10.05, 16.17, 19.23, 21.60, 24.08, 25.22, 26.60 and 27.32 ± 0.2 °2Θ. The XRPD diffractogram may comprise still further peaks at 1 1.37, 12.75, 15.47 and 20.13 ± 0.2 °2Θ. The XRPD diffractogram may be as depicted in Figure 1.
Crystalline Form I raloxifene oxalate ethanolate sesquihydrate may be characterized by having an intrinsic dissolution profile as shown in Figure 2.
According to another aspect of the present invention, there is provided a process for preparing crystalline raloxifene oxalate ethanolate sesquihydrate, the process comprising forming a solution of raloxifene base and oxalic acid di hydrate in ethanol at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature. The raloxifene, as free base, may be in any polymorphic form or in a mixture of any polymorphic forms.
More particularly, the present invention provides a process for preparing crystalline Form I raloxifene oxalate ethanolate sesquihydrate as defined above and in the claims, the process comprising dissolving raloxifene base in ethanol at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in ethanol to form a reaction mass, and isolating crystalline Form I. The oxalic acid is typically added at a temperature ranging from 40°C to 60°C, preferably at a temperature ranging from 50°C to 55°C. The oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1.5 hours, more preferably for a time of around 50 minutes to 1 hour 0 minutes, for example over a period of around 60 minutes.
The isolation may comprise isolating precipitated Form I from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30°C to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours. Immediately prior to the drying step, the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
The process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid. Suitably, the stirring takes place for at least 7 hours, for example around 8 hours.
The raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide. For example, the other salt may be raloxifene hydrochloride.
According to another aspect of the present invention, there is provided crystalline raloxifene oxalate ethanolate sesquihydrate Form I prepared by a process according to the process described above. The process produces crystalline raloxifene oxalate ethanolate sesquihydrate in high yield and purity.
The derivate of raloxifene oxalate may be a non-solvated hydrate of raloxifene oxalate. Preferably, the hydrate is a hemihydrate. The inventors have discovered a surprisingly advantageous polymorphic form of raloxifene oxalate which is crystalline Form II raloxifene oxalate monohydrate. This form is described in more detail herein.
According to another aspect of the present invention, there is provided crystalline raloxifene oxalate monohydrate wherein the said crystal form of this embodiment is referred to as Form II. The crystalline raloxifene oxalate monohydrate Form II according to the present invention may be characterized by powder X-ray difractogram.
Crystalline raloxifene oxalate monohydrate Form II may be characterized by having an XRPD diffractogram comprising peaks at 14.94, 18.60 and 20.34 ± 0.2 °2Θ. The XRPD diffractogram may comprise further peaks at 20.04, 21.90 and 22.72 ± 0.2 "2Θ. The XRPD
diffractogram may comprise still further peaks at 7.00, 10.00 and 16.12 ± 0.2 °2Θ. The XRPD diffractogram may be as depicted in Figure 3.
According to another aspect of the present invention, there is provided a process for preparing crystalline raloxifene oxalate monohydrate, the process comprising forming a solution of raloxifene base and oxalic acid dihydrate in methanol solvent at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature. More particularly, the present invention provides a process for preparing crystalline raloxifene oxalate monohydrate Form II as defined herein and in the claims, the process comprising dissolving raloxifene base in methanol at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in methanol to form a reaction mass, and isolating crystalline Form II. The oxalic acid is typically added at a temperature ranging from 40° C to 60°C, preferably at a temperature ranging from 50°C to 55°C. The oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1.5 hours, more preferably for a time of around 50 minutes to 1 hour 10 minutes, for example over a period of around 60 minutes.
The isolation may comprise isolating precipitated Form II from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30CC to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours. Immediately prior to the drying step, the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
The process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid. Suitably, the stirring takes place for at least 7 hours, for example around 8 hours. The raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide. For example, the other salt may be raloxifene hydrochloride. The raloxifene, as free base may be, in any polymorphic form or in a mixture of any polymorphic forms.
According to another aspect of the present invention, there is provided crystalline raloxifene oxalate monohydrate Form II prepared by a process according to the process described above. The process produces crystalline raloxifene oxalate Form II in high yield and purity.
According to another aspect of the present invention, there is provided crystalline raloxifene oxalate isopropanolate hemihydrate wherein the said crystal form of this embodiment is referred to as Form III.
The crystalline raloxifene oxalate isopropanolate hemihydrate Form III according to the present invention may be characterized by powder X-ray diffractogram. Crystalline raloxifene oxalate isopropanolate hemihydrate Form III may be characterized by having an XRPD diffractogram comprising a peak at 21.38 ± 0.2 °2Θ. The XRPD diffractogram may comprise further peaks at 15.64, 18.69, 19.42, 23.16, 24.18 and 26. 0 ± 0.2 °2Θ. The XRPD diffractogram may comprise still further peaks at 11.90 ± 0.2 °2Θ. The XRPD diffractogram may be as depicted in Figure 4.
According to another aspect of the present invention, there is provided a process for preparing crystalline raloxifene oxalate isopropanolate hemihydrate Form III, the process comprising forming a solution of raloxifene base and oxalic acid dihydrate in isopropanol solvent at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature.
The raloxifene, as free base, may be in any polymorphic form or in a mixture of any polymorphic forms. More particularly, the present invention provides a process for preparing crystalline raloxifene oxalate isopropanolate hemihydrate Form III as defined herein and in the claims, the process comprising dissolving raloxifene base in isopropanol at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in isopropanol to form a reaction mass, and isolating crystalline Form III. The oxalic acid is typically added at a temperature ranging from 40°C to 60°C, preferably at a temperature ranging from 50°C to 55°C. The oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1 .5 hours, mere preferably for a time of around 50 minutes to 1 hour 10 minutes, for example over a period of around 60 minutes.
The isolation may comprise isolating precipitated Form III from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30°C to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours. Immediately prior to the drying step, the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
The process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid. Suitably, the stirring takes place for at least 7 hours, for example around 8 hours. The raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide. For example, the other salt may be raloxifene hydrochloride. According to another aspect of the present invention, there is provided crystalline raloxifene oxalate isopropanolate hemihydrate Form III prepared by a process according to the process described above. The process produces crystalline raloxifene oxalate isopropanolate hemihydrate Form III in high yield and purity. According to another aspect of the present invention, there is provided crystalline raloxifene oxalate THF (tetrahydrofuran) hemisolvate monohydrate wherein the said crystal form of this embodiment is referred to as Form IV.
The crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV according to the present invention may be characterized by powder X-ray difractogram.
Crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV may be characterized by having an XRPD diffractogram comprising peaks at 18.48, 19.46 and 21.2 ± 0.2 °2Θ. The XRPD diffractogram may comprise further peaks at 10.79, 11.54, 12.02, 16.66, 17.43, 19.80, 24.30 and 24.58 ± 0.2 °2Θ. The XRPD diffractogram may be as depicted in Figure 5.
According to another aspect of the present invention, there is provided a process for preparing crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV, the process comprising forming a solution of raloxifene base and oxalic acid dihydrate, in THF
solvent at an appropriate temperature; promoting crystal growth and collecting the crystals, preferably by filtration and drying at elevated temperature.
The raloxifene, as free base, may be in any polymorphic form or in a mixture of any polymorphic forms.
More particularly, the present invention provides a process for preparing crystalline raloxifene oxalate THF hemisolvate monchydrate Form IV as defined above and in the claims, the process comprising dissolving raloxifene base in THF at a temperature ranging from 40°C to 60°C (preferably the temperature ranges from 50°C to 55°C), adding a solution of oxalic acid dihydrate in THF to form a reaction mass, and isolating crystalline Form IV. The oxalic acid is typically added at a temperature ranging from 40°C to 60°C, preferably at a temperature ranging from 50°C to 55°C. The oxalic acid is typically added over a period ranging from around 30 minutes to around 2 hours, preferably from around 45 minutes to around 1.5 hours, more preferably for a time of around 50 minutes to 1 hour 10 minutes, for example over a period of around 60 minutes.
The isolation may comprise isolating precipitated Form IV from the reaction mass, followed by drying under reduced pressure at a temperature ranging from around 30°C to around 90°C (preferably at a temperature ranging from around 60°C to around 85°C; more preferably ranging from around 70°C to around 85°C) for at least 8 hours, preferably at a temperature ranging from 75°C to 85°C for around 8 hours. Immediately prior to the drying step, the reaction mass may be cooled to a temperature ranging from around 20°C to around 35°C; preferably ranging from around 25°C to around 35°C).
The process may further comprise stirring the reaction mass for at least 5 hours prior to the isolation step and after the addition of the oxalic acid. Suitably, the stirring takes place for at least 7 hours, for example around 8 hours.
The raloxifene base may be prepared from a salt of raloxifene, other than raloxifene oxalate, the preparation of the free base from the salt being carried by any well known method, for example reaction of the salt with a base such as sodium hydroxide. For example, the other salt may be raloxifene hydrochloride.
According to another aspect of the present invention, there is provided crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV prepared by a process according to the process described above. The process produces crystalline raloxifene oxalate THF solvate Form IV in high yield and purity.
In preparing Forms I, II, III and IV as defined herein and in the claims, the oxalic acid being in the form of a dihydrate provides the water for hydration.
According to another aspect of the present invention, there is provided a pharmaceutical composition comprising raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, Crystalline Form II of raloxifene oxalate monohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate), together with one or more pharmaceutically acceptable excipients, including pharmaceutically acceptable carriers.
Suitably, the pharmaceutical composition is in the form of a tablet suitable for oral delivery. According to another aspect of the present invention, there is provided raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, Crystalline Form II of raloxifene oxalate monohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate) for use in medicine. Suitably, the raloxifene oxalate is for use in
treating osteoporosis (particularly in postmenopausal women), breast cancer (particularly in postmenopausal women) and/or cartilage degradation.
According to another aspect of the present invention, there is provided the use of raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesqui hydrate, Crystalline Form II of raloxifene oxalate mortohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate) for use in the manufacture of a medicament for treating or preventing osteoporosis (particularly in postmenopausal women), breast cancer (particularly in postmenopausal women) and/or cartilage degradation.
According to another aspect of the present invention, there is provided a method of treating or preventing osteoporosis (particularly in postmenopausal women), breast cancer (particularly in postmenopausal women) and/or cartilage degradation, comprising administering to a patient in need thereof a therapeutically effective amount of raloxifene oxalate as described above (including Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, Crystalline Form II of raloxifene oxalate monohydrate, Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate; preferably Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate).
Brief Description of the Drawing Figure 1 is X-ray powder diffraction spectrum of crystalline raloxifene oxalate ethanolate sesquihydrate Form I.
Figure 2 is the Intrinsic Dissolution Rate for crystalline raloxifene oxalate ethanolate sesquihydrate Form I compared with raloxifene hydrochloride
Figure 3 is X-ray powder diffraction spectrum of crystalline raloxifene oxalate monohydrate Form II.
Figure 4 is X-ray powder diffraction spectrum of crystalline raloxifene oxalate isopropanolate hemihydrate Form III.
Figure 5 is X-ray powder diffraction spectrum of crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV. Detailed Description Of The Invention
As used herein, the term "solvated" is understood to mean formation of a complex of variable stoichiometry comprising raloxifene of Formula (I) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Typically, the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include C1-C4 alcohol solvents and tetrahydrofuran (THF), and solvates other than water at levels of more than 1%.
The solvate can be isolated either as an amorphous form or in a crystalline form, preferably in crystalline form.
The solvate can be further isolated either in anhydrous form or hydrated form.
As used herein, the term "hydrate" is understood as a substance that is formed by adding water molecules. The skilled person will appreciate that the water molecules are absorbed, adsorbed or contained within a crystal lattice of the solid compounds, usually in defined stoichiometric ratio. The notation for a hydrated compound may be .nH20, where n is the number of water molecules per formula unit of the compound. For example, in a hemihydrate, n is 0.5; in a monohydrate n is one; in a sesquihydrate, n is 1.5; in a dihydrate, n is 2; and so on.
As used herein, the term "substantially the same X-ray powder diffraction pattern" is understood to mean that those X-ray powder diffraction patterns having diffraction peaks with 2Θ values within ± 0.2° of the diffraction pattern referred to herein are within the scope of the referred to diffraction pattern.
In one aspect the present invention provides the oxalic acid addition salt of raloxifene. The oxalate may be isolated in pseudopolymorphic form as a solvate optionally in hydrated form, or as a non-hydrated solvate.
Accordingly, pseudopolymorphs provided include solvates, more in particular, a THF solvate, or a C1-C4 alcohol solvate, optionally in hydrated form.
Because oxalic acid has two acid groups per molecule, compounds of these acids and raloxifene may be isolated as either mono- or di-acid addition salts and/or solvates thereof having either one or two raloxifene molecules per acid molecule respectively.
The ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
As polymorphic forms are reliably characterized by peak positions in the X-ray diffractogram, the polymorphs of the present invention have been characterized by powder X-ray diffraction spectroscopy which produces a fingerprint of the particular crystalline form. Measurements of 2Θ values are accurate to within ± 0.2 degrees. All the powder diffraction patterns were measured on a Rigaku Dmax 2200 advanced X-ray powder diffractometer with a copper-Κ-α radiation source.
The invention further provides processes for the preparation of polymorphs.
Thus, in one aspect, the present invention provides the crystalline raloxifene oxalate ethanolate hydrate.
In an embodiment, raloxifene oxalate ethanolate referred in this specification includes various degrees of hydrates. Preferably, the hydrate is sesquihydrate.
Thus in a preferred embodiment the acid addition salt and/or solvates thereof according to the invention is raloxifene oxalate ethanolate hydrate, and in a particular preferred embodiment the acid addition salt is crystalline raloxifene oxalate ethanolate sesquihydrate which is herein and in the claims designated as Form I which is substantially non-hygroscopic and has good flow characteristics.
In another aspect, the present invention provides a process for preparing the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate in high yield and purity. The present invention also provides pharmaceutical compositions comprising the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate.
The ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
In an embodiment, the ethanol content in raloxifene oxalate may vary in ratio depending on the conditions applied. Conveniently, the ratio of raloxifene to the ethanol may range between 2.5wt% (0.5 moles) to 5.0wt% (1.0 mole). While the raloxifene oxalate, comprising 0.5 molecules of ethanol per molecule of raloxifene and about 1 molecule of ethanol per molecule of raloxifene represent the lower and upper ranges respectively, ethanol content of the crystal form may vary within this range depending on the temperature of the crystal form.
Thus, raloxifene oxalate forms a crystalline sesquihydrate with ethanol wherein the molar ratio of raloxifene to oxalic acid to water is approximately 2:1 :1.5 whereas ethanol is present in the non-stoichiometric ratio ranging from 2.5% (0.5 moles) to 5.0% (1.0 mole). Accordingly, the present invention provides crystalline Form I of raloxifene oxalate ethanolate sesquihydrate, methods of preparing the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate in high purity and high yield and pharmaceutical compositions comprising them. The advantages of the process include simplicity, eco-friendliness and suitability for commercial use.
The crystalline Form I of raloxifene oxalate ethanolate sesquihydrate thereof according to the invention has dissolution properties in dilute hydrochloric acid that secure a high bioavailability of the compound. In particular the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate according to the invention has higher intrinsic dissolution rates in dilute hydrochloric acid compared with free raloxifene.
In an embodiment, the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate has an XRD pattern with characteristics peaks at 8.59, 9.03 and 14.22 ± 0.2 °2Θ. The crystalline Form I of raloxifene oxalate ethanolate sesquihydrate may have an XRD pattern with characteristics peaks at 8.59, 9.03, 14.22, 17.16, 23.26 and 24.74 ± 0.2 °2Θ. The XRD pattern may have further peaks at 10.05, 16.17, 19.23, 21.60, 24.08, 25.22, 26.60 and 27.32 ± 0.2 °2Θ. The XRD pattern may have still further peaks at 1 1.37, 12.75, 15.47 and 20.13 ± 0.2 °2Θ.
In an embodiment, the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate has an XRPD pattern with those peaks at °2Θ values ± 0.2 °2Θ as depicted in Table 1. In an embodiment, the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate has substantially the same XRPD pattern with peaks at 2Θ values as depicted in Table 1.
Table 1 : Table of values for the XRPD pattern depicted in Figure 1
Peak value (°2Θ) Relative Intensity [%]
8.59 76.1
9.03 100.0
10.05 68.8
11.37 27.4
12.75 20.4
13.22 14.2
14.22 99.1
15.47 22.8
16.17 55.3
16.60 12.2
17.16 82.8
18.16 15.3
18.42 17.9
19.23 58.3
20.13 28.4
21.60 38.2
22.25 9.6
23.26 95.8
24.08 44.8
24.74 78.4
25.22 51.0
26.60 36.0
27.32 44.9
29.22 19.7
30.00 10.6
In an embodiment, the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate of the present invention is characterized by having an intrinsic dissolution profile as shown in Figure 2. To measure the intrinsic dissolution of the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate and raloxifene hydrochloride, samples were measured to compare the influence of the different parameter settings. At appropriate time intervals, an automated sample collector removes aliquots from dissolution medium for analysis. The time interval for sampling can vary, for example, from 2 to 30 minutes, depending on the properties of the drug and dissolution medium used. Suitable dissolution equipment for these operations includes LAB INDIA DISSO 2000.
Those skilled in the art would recognize that Form I may be further characterized by other methods including, but not limited to IR, solid state NMR and Raman spectroscopy.
According to another aspect of the present invention there is provided a process for the preparation of the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate. The process may comprise: dissolving raloxifene base in ethanol at 40-60°C, adding a solution of oxalic acid dihydrate in ethanol, stirring for at least 5 hours, isolating the precipitated crystalline Form I of raloxifene oxalate ethanolate sesquihydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hrs.
Alternatively, the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate may be prepared by a process comprising; converting any acid addition salt of raloxifene into the free base and subsequently converting free base into the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate.
The raloxifene acid addition salt used in the preparation of the Form I may be in any polymorphic form or in a mixture of any polymorphic forms wherein the said raloxifene in hydrated, solvated, non-solvated or mixture of hydrated, solvated or non-solvated forms
thereof. In a preferred embodiment, raloxifene is provided in the form of raloxifene hydrochloride.
The raloxifene hydrochloride, used for the above process, as well as for the following processes, describe in this application can be obtained by any method known to a skilled artisan.
The crystalline Form I of raloxifene oxalate ethanolate sesquihydrate obtained according to the present invention is substantially free from other forms of raloxifene. "Substantially free" from other forms of raloxifene shall be understood to mean that the polymorphs of raloxifene contain less than 10%, preferably less than 5%, of any other forms of raloxifene and less than 1 % of other impurities or solvates.
The process of invention may be used as a method for purifying any form of raloxifene, as well as for the preparation of the new polymorphic forms.
According to yet another aspect of the present invention, there is provided use of the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate as described above, in the preparation of a medicament useful in treating or preventing osteoporosis and breast cancer in postmenopausal women and for treating cartilage degradation.
Yet another aspect of the present invention provides a novel polymorphic form of raloxifene oxalate monohydrate which is hereinafter designated as Form II which is substantially non-hygroscopic and has good flow characteristics.
The ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
Thus, raloxifene oxalate forms a crystalline monohydrate with water wherein the molar ratio of raloxifene to oxalic acid to water is approximately 2:1:1.
In another aspect, the present invention provides a process for preparing the novel Form II of raloxifene oxalate monohydrate in high yield and purity. The present invention also provides pharmaceutical compositions comprising Form II of raloxifene oxalate monohydrate.
In an embodiment, the crystalline polymorph Form II of raloxifene oxalate monohydrate has an XRD pattern with characteristics peaks at 14.94, 18.60 and 20.34 ± 0.2 °2Θ. The XRD pattern may be further characterized by an XRD with peaks at 20.04, 21.90 and 22.72 ± 0.2 °2Θ. The XRD pattern comprises still further peaks at 7.00, 10.00 and 16.12 ± 0.2 "2Θ. In an embodiment, the crystalline polymorph Form II of raloxifene oxalate monohydrate has substantially the same XRPD pattern with peaks at 2Θ values as depicted in Table 2.
Table 2: Table of values for the XRPD pattern depicted in Figure 3
Peak value (°2Θ) Relative Intensity [%]
7.00 27.2
10.00 26.7
11.64 12.1
12.02 13.9
13.40 19.7
13.97 6.4
14.94 80.50
16.12 24.5
17.36 12.0
18.60 100.0
20.04 60.2
20.34 72.3
21.90 31.9
22.72 57.8
24.30 18.4
24.90 4.1
25.94 13.3
28.86 9.1
29.89 15.1
30.48 5.7
In an embodiment, the crystalline polymorph Form II of raloxifene oxalate monohydrate has substantially the same XRPD pattern with peaks at 2Θ values as depicted in Figure 3. Those skilled in the art would recognize that Form II may be characterized by other methods including but not limited to IR, solic" state NMR and Raman spectroscopy.
According to another aspect of the present invention there is provided a process for the preparation of crystalline Form II of raloxifene oxalate monohydrate. The process may comprise the steps of: dissolving raloxifene base in methanol at 55-60°C, adding a solution of oxalic acid dihydrate in methanol, stirring for at least 8 hours, isolating the precipitated crystalline Form II of raloxifene oxalate monohydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hrs. The present invention further provides a novel polymorph form of raloxifene oxalate isopropanolate hemihydrate which is hereinafter designated as Form III which is substantially non-hygroscopic and has good flow characteristics.
The ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Thus, raloxifene oxalate forms a crystalline hemihydrate with isopropanol wherein the molar ratio of raloxifene to oxalic acid to IPA to water is approximately 2:1 :2:0.5.
In another aspect, the present invention provides a process for preparing the novel Form III of raloxifene oxalate isopropanolate hemihydrate in high yield and purity. The present invention also provides pharmaceutical compositions comprising Form III of raloxifene oxalate isopropanolate hemihydrate.
In an embodiment, the crystalline polymorph Form III of raloxifene oxalate isopropanolate hemihydrate has an XRD pattern with a characteristic peak at 2 .38 ± 0.2 "2Θ. The XRD pattern may be further characterized by an XRD with peaks at 15.64, 18.69, 19.42, 23.16, 24.18 and 26.10 ± 0.2 °2Θ. The XRD pattern comprises a still further peak at 1 1.90 ± 0.2 °2Θ.
In an embodiment, the crystalline polymorph Form III of raloxifene oxalate isopropanolate hemihydrate has substantially the same XRPD pattern with peaks at 2Θ values as depicted in Table 3.
Table 3: Table of values for the XRPD pattern depicted in Figure 4
In an embodiment, the crystalline polymorph Form III of raloxifene oxalate isopropanolate hemihydrate has substantially the same XRPD pattern with peaks at 2Θ values as depicted in Figure 4.
Those skilled in the art would recognize that Form III may be characterized by other methods including but not limited to IR, solid state NMR and Raman spectroscopy.
According to another aspect of the present invention there is provided a process for the preparation of crystalline Form III of raloxifene oxalate isopropanolate hemihydrate. The process may comprise the steps of dissolving raloxifene base in isopropanol at 55-60°C, adding a solution of oxalic acid dihydrate in isopropanol, stirring for at least 8 hours, isolating the precipitated crystalline Form III of raloxifene oxalate isopropanolate hemihydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hrs.
Yet another aspect of the present invention provides a novel polymorphic form of raloxifene oxalate THF hemisolvate monohydrate which is hereinafter designated as Form IV which is substantially non-hygroscopic and has good flow characteristics.
The ratio of raloxifene of formula I to oxalic acid may range from about 1 to about 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid. Preferably, the ratio is 2 molecules of raloxifene of formula I per 1 molecule of oxalic acid.
Thus, raloxifene oxalate forms a crystalline hemisolvate with THF wherein the molar ratio of raloxifene to oxalic acid to THF to water is approximately 2:1 :0.5:1. In another aspect, the present invention provides a process for preparing the novel Form IV of raloxifene oxalate THF hemisolvate monohydrate in high yield and purity. The present invention also provides pharmaceutical compositions comprising Form IV of raloxifene oxalate THF hemisolvate monohydrate. In an embodiment, the crystalline polymorph Form IV of raloxifene oxalate THF hemisolvate monohydrate has an XRD pattern with characteristics peaks at 18.48, 19.46 and 21.2 ± 0.2 °2Θ. The XRD pattern may be further characterized by an XRD with peaks at 10.79, 11.54, 12.02, 16.66, 17.43, 19.80, 24.30 and 24.58 ± 0.2 °2Θ. The XRD pattern comprises still further peaks at 20.62 and 25.64 ± 0.2 °2Θ.
In an embodiment, the crystalline polymorph Form IV of raloxifene oxalate THF hemisolvate monohydrate has substantially the same XRPD pattern with peaks at 2Θ values as depicted in Table 4. Table 4: Table of values for the XRPD pattern depicted in Figure 5
Peak value (°2Θ) Relative Intensity
[%]
6.82 19.5
7.61 8.5
8.98 7.5
9.83 11.5
10.79 59.6
11.54 37.5
i
12.02 51.7
13.62 12.8
16.66 55.0
17.43 30.1
18.48 100.0
19.46 76.5
19.80 58.7
20.62 20.0
21.20 82.5
22.23 17.1
23.18 15.5
24.30 44.0
24.58 38.2
25.64 24.1
27.48 13.2
In an embodiment, the crystalline polymorph Form IV of raloxifene oxalate THF hemisolvate monohydrate has substantially the same XRPD pattern with peaks at 2Θ values as depicted in Figure 5. Those skilled in the art would recognize that Form IV may be characterized by other methods including but not limited to IR, solid state NMR and Raman spectroscopy.
According to another aspect of the present invention there is provided a process for the preparation of crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate. The process may comprise the steps of: dissolving raloxifene base in THF at 55-60°C, adding a solution of oxalic acid dihydrate in THF, stirring for at least 8 hours, isolating the precipitated crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate and drying under reduced pressure at 30-80°C, preferably at 60-80°C for at least 8 hours. The process of invention may be used as a method for purifying any form of raloxifene oxalate, as well as for the preparation of the new polymorphic forms.
According to another aspect of the present invention, there is provided a pharmaceutical composition comprising polymorphic forms of raloxifene oxalate as described above, together with one or more pharmaceutically acceptable excipients. The raloxifene oxalate used in the preparation of pharmaceutical compositions may substantially consist of one of forms I, II, III or IV described above, or may substantially consist of a combination of two or more of said forms. According to yet another aspect of the present invention there is provided use of polymorphic Forms of raloxifene oxalate as described above, in the preparation of a medicament useful in treating or preventing osteoporosis and breast cancer in postmenopausal women and for treating cartilage degradation.
The invention will now be further described by the following examples, which are illustrative rather than limiting.
Examples 1
a) Preparation of raloxifene base:
Raloxifene HCI (200 gm) was stirred with methanol (2000 ml) at room temperature. An aqueous solution of sodium hydroxide (50 gm dissolved in 200 ml of water) was added, stirred and cooled to 15°C - 20°C.The pH of the reaction mass was adjusted to 8.0 to 8.5 using 20% aqueous HCI solution. The temperature of the reaction mass was raised to 25°C - 30°C and stirred for 12 hours. To the reaction mass was added water (4000 ml) and the pH was adjusted to 8.0 - 8.5 using 10% aqueous NaOH solution and stirred for 30 minutes. The product was isolated by filtration, washed with water (100 ml) and dried under vacuum at 85°C - 95°C for 8 hours to yield 180 gm of titled compound. b) Preparation of crystalline Form I of raloxifene oxalate ethanolate sesquihydrate:
Raloxifene Base (180 gm) was dissolved in ethanol (1800 ml) at 50°C-55CC. A solution of oxalic acid dihydrate (23.01 gm in 460 ml of ethanol) was added slowly at 50°C-55°C over a period of 60 minutes and stirred for 8 hours. The reaction mass cooled to 25°C - 30°C, stirred for 30 minutes. The solid was isolated by filtration, washed with ethanol (100 ml) and dried under vacuum at 75°C - 85°C for 8 hours to yield 190 gm of titled compound.
Example 2
Comparative Intrinsic Dissolution Study
Preparation of tablet- General process for preparing tableting mixture comprising crystalline Form I of raloxifene oxalate ethanolate sesquihydrate:-
A tableting mixture (50 mg) comprising solely crystalline Form I of raloxifene oxalate ethanolate sesquihydrate prepared according to the example 1 (i.e. with no excipients),
was prepared and compressed to a pellet using a manual hand press operating at a compression pressure of 1 ton for 1 minute.
In-vitro dissolution studies were performed on the 50 mg pellet in a LAB INDIA DISSO 2000.
The pellet was fixed in a PFTE holder, such that only the pellet surface came into contact with the dissolution medium. The PFTE loaded holder was placed in the dissolution vessel containing 900 ml of 2% SLS (sodium lauryl sulphate) in water at 35°C - 40°C. Two pellets were measured for each run of the design of the experiments. Stirring was performed with a paddle rotating at 100 rpm. The dissolution was followed up to 1440 min and the concentration of active ingredient, raloxifene, dissolved in the test medium was determined by removing samples of 10 ml at the specified time intervals.
The concentration of crystalline Form I of raloxifene oxalate ethanolate sesquihydrate was quantified by UV method at a maximum wavelength of 280 nm under the conditions as specified below:
Standard Preparation: 50 mg raloxifene hydrochloride dissolved to 50 ml with Acetonitrile
Water (1 :1).
5 ml of this solution diluted to 00 ml with dissolution medium.
2 ml of this solution further diluted to 5 ml with purified water.
Sample Aliquot: 2 ml of aliquot further diluted to 5 ml with purified water.
Blank Purified water:Dissolution medium (2:3)
Diluent Acetonitrile: water (1 :1)
Wavelength 280nm
Path length 1 cm (Covet size)
The percentage of raloxifene released from the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate as well as from the raloxifene hydrochloride physical mixture
were plotted against time as shown in Figure 2. The intrinsic dissolution rate was derived from the slope of this curve. Table 2 shows the results in tabular form.
Table 2: Intrinsic Dissolution Profile of crystalline Form I of raloxifene oxalate ethanolate sesquihydrate with raloxifene hydrochloride
When compared with raloxifene hydrochloride, the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate exhibited a superior rate of dissolution as shown in Table 2. The peak dissolution of 82.0 % was achieved at 1080 min for the crystalline Form I of
raloxifene oxalate ethanolate sesquihydrate; whereas, at the same time, 62.0 % was achieved for raloxifene hydrochloride. Thus, another aspect of the present invention is crystalline Form I of raloxifene oxalate ethanolate sesquihydrate characterised by a peak dissolution (typically when measured at a temperature ranging from 35°C to 40°C) of at least around 75%, preferably at least around 79%, more preferably at least around 81%, particularly when dissolution is measured in accordance with the above procedure. Typically, the crystalline Form I of raloxifene oxalate ethanolate sesquihydrate is characterised when in the form of a compressed tablet. Example 3
Preparation of crystalline Form II of raloxifene oxalate monohydrate:
Raloxifene Base (10 gm) was dissolved in methanol (100 ml) at 50°C - 55°C. A solution of oxalic acid dihydrate (1.27 gm in 25 ml of methanol) was added slowly at 50°C - 55°C over a period of 60 minutes and stirred for 8 hours. The reaction mass cooled to 25°C - 30°C, stirred for 30 minutes. The solid was isolated by filtration, washed with methanol (10 ml) and dried under vacuum at 75°C -85°C for 8 hours to yield 9.0 gm of titled compound.
Example 4
Preparation of crystalline Form III of raloxifene oxalate isopropanolate hemihydrate: Raloxifene Base (10 gm) was dissolved in isopropanol (100 ml) at 50X - 55°C. A solution of oxalic acid dihydrate (1.27 gm in 25 ml of isopropanol) was added slowly at 50°C - 55°C over a period of 60 minutes and stirred for 8 hours. The reaction mass cooled to 25°C - 30°C, stirred for 30 minutes. The solid was isolated by filtration, washed with isopropanol (10 ml) and dried under vacuum at 75°C -85°C for 8 hours to yield 9.2 gm of titled compound.
Example 5
Preparation of crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate:
Raloxifene Base (10 gm) was dissolved in THF (100 ml) at 50°C - 55°C. A solution of oxalic acid dihydrate (1.27 gm in 25 ml of THF) was added slowly at 50°C - 55°C over a period of 60 minutes and stirred for 8 hours. The reaction mass cooled to 25°C - 30°C, stirred for 30 minutes. The solid was isolated by filtration, washed with THF (10 ml) and dried under vacuum at 75°C -85°C for 8 hours to yield 9.7 gm of titled compound. It will be appreciated that the invention may be modified within the scope of the appended claims.
Claims
1. Raloxifene oxalate.
2. Raloxifene oxalate according to claim 1 , wherein the raloxifene oxalate is in the form of a pharmaceutically acceptable derivative, which optionally comprises a pharmaceutically acceptable solvate, hydrate, ester, tautomer, anhydrate, complex, polymorph, prodrug or combination thereof.
3. Raloxifene oxalate as claimed in claim 1 or 2, wherein the raloxifene oxalate is a raloxifene oxalate solvate optionally in hydrated form.
4. Raloxifene oxalate as claimed in claim 3, which is a raloxifene oxalate solvate hydrate.
5. Raloxifene oxalate as claimed in claim 3 or 4, wherein the solvate is a C1-C4 alcoholate.
6. Raloxifene oxalate as claimed in claim 5, which is an ethanolate.
7. Raloxifene oxalate as claimed in any one of claims 2 to 6, which is a hydrate.
8. Raloxifene oxalate as claimed in claim 7, which is raloxifene oxalate ethanolate sesqui hydrate.
9. Raloxifene oxalate as claimed in claim 8, which is crystalline Form I raloxifene oxalate ethanolate sesquihydrate.
10. Crystalline Form I raloxifene oxalate ethanolate sequihydrate as claimed in claim 9, characterized by having an XRPD diffractogram comprising peaks at 8.59, 9.03,14.22, 17.16, 23.26 and 24.74 ± 0.2 °2Θ.
11. Crystalline Form I raloxifene oxalate ethanolate sesquihydrate as claimed in claim 10, having an XRPD diffractogram comprising further peaks at 10.05, 16.17, 19.23, 21.60, 24.08, 25.22, 26.60 and 27.32 ± 0.2 °2Θ.
12. Crystalline Form I raloxifene oxalate ethanolate sesquihydrate as claimed in claim 11 , having an XRPD diffractogram comprising further peaks at 11.37, 12.75, 15.47 and
20.13 ± 0.2 °2Θ.
13. Crystalline Form I raloxifene oxalate ethanolate sesquihydrate as claimed in any one of claims 9 to 12, characterized by having art XRPD diffractogram as depicted in Figure 1.
14. Crystalline Form I raloxifene oxalate ethanolate sesquihydrate as claimed in any one of claims 9 to 13 characterized by having an intrinsic dissolution profile as shown in Figure 2.
15. Raloxifene oxalate as claimed in claim 1 , which is raloxifene oxalate monohydrate.
16. Raloxifene oxalate as claimed in claim 15, which is crystalline raloxifene oxalate monohydrate Form II.
17. Crystalline raloxifene oxalate monohydrate Form II as claimed in claim 16, characterized by having an XRPD diffractogram comprising peaks at 14.94, 18.60 and 20.34 ± 0.2 °2Θ.
18. Raloxifene oxalate as claimed in claim 1 , which is raloxifene oxalate isopropanolate hemihydrate.
19. Raloxifene oxalate as claimed in claim 18, which is crystalline raloxifene oxalate isopropanolate hemihydrate Form III.
20. Crystalline raloxifene oxalate isopropanolate hemihydrate Form III as claimed in claim 19, characterized by having an XRPD diffractogram comprising a peak at 21.38 ± 0.2 °2Θ.
21. Raloxifene oxalate as claimed in claim 1 , which is raloxifene oxalate THF hemisolvate monohydrate.
22. Raloxifene oxalate as claimed in claim 21 , which is crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV.
23. Crystalline raloxifene oxalate THF hemisolvate monohydrate Form IV as claimed in claim 22, characterized by having an XRPD diffractogram comprising peaks at 18.48, 19.46 and 21.2 ± 0.2 °2Θ.
24. A process for preparing crystalline Form I raloxifene oxalate ethanolate sesquihydrate as claimed in any one of claims 9 to 14, the process comprising dissolving raloxifene base in ethanol at a temperature ranging from 40°C to 60°C, adding a solution of oxalic acid dihydrate in ethanol to form a reaction mass, and isolating crystalline Form I.
25. A process as claimed in claim 24, wherein the isolation comprises isolating precipitated Form I from the reaction mass, followed by drying under reduced pressure at a temperature ranging from 30°C to 90°C for at least 8 hours, preferably at a temperature ranging from 60°C to 80°C for at least 8 hours.
26. A process as claimed in claim 24 or 25, further comprising stirring the reaction mass for at least 5 hours prior to isolation.
27. A process as claimed in any one of claims 24 to 26, wherein the raloxifene base is in any polymorphic form or in a mixture of any polymorphic forms.
28. A process as claimed in any one of claims 24 to 27, wherein the raloxifene base is prepared from a salt of raloxifene, other than raloxifene oxalate.
29. A process as claimed in claim 28, wherein the salt used to prepare raloxifene base is raloxifene hydrochloride.
30. Crystalline Form I raloxifene oxalate ethanolate sesquihydrate prepared by a process according to any one of claims 24 to 29.
31. A pharmaceutical composition comprising raloxifene oxalate according to any one of claims 1 to 23 or 30, together with one or more pharmaceutically acceptable excipients.
32. A pharmaceutical composition according to claim 31 , which is in the form of a tablet suitable for oral delivery.
33. Raloxifene oxalate as claimed in any one of claims 1 to 23 or 30 or a pharmaceutical composition as claimed in claim 31 or 32, for use in treating or preventing osteoporosis, breast cancer and/or cartilage degradation.
34. A method of treating or preventing osteoporosis, breast cancer and/or cartilage degradation comprising administering to a patient in need thereof raloxifene oxalate as claimed in any one of claims 1 to 23 or 30 or a pharmaceutical composition as claimed in claim 31 or 32.
35. Crystalline Form I of raloxifene oxalate ethanolate sesquihydrate substantially as herein described with reference to Example 1 (b).
36. Crystalline Form II of raloxifene oxalate monohydrate substantially as herein described with reference to Example 3.
37 Crystalline Form III of raloxifene oxalate isopropanolate hemihydrate substantially as herein described with reference to Example 4. 38. Crystalline Form IV of raloxifene oxalate THF hemisolvate monohydrate substantially as herein described with reference to Example 5.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN665/MUM/2013 | 2013-03-05 | ||
IN665MU2013 IN2013MU00665A (en) | 2013-03-05 | 2014-03-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2014135834A1 true WO2014135834A1 (en) | 2014-09-12 |
WO2014135834A8 WO2014135834A8 (en) | 2014-11-27 |
Family
ID=50382470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2014/000081 WO2014135834A1 (en) | 2013-03-05 | 2014-03-05 | Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator |
Country Status (3)
Country | Link |
---|---|
IN (1) | IN2013MU00665A (en) |
WO (1) | WO2014135834A1 (en) |
ZA (1) | ZA201401636B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017107754A1 (en) | 2015-12-22 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | Benzopiperidine derivative, preparation method thereof and medical use thereof |
US10087191B2 (en) | 2015-06-16 | 2018-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
WO2021139756A1 (en) | 2020-01-10 | 2021-07-15 | 江苏恒瑞医药股份有限公司 | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine |
WO2023280309A1 (en) | 2021-07-09 | 2023-01-12 | 江苏恒瑞医药股份有限公司 | Salt types of tricyclic tetrahydro isoquinoline derivative |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4358593A (en) | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
EP0584952A1 (en) | 1992-07-28 | 1994-03-02 | Eli Lilly And Company | Improvements in or relating to benzothiophenes |
WO1996009045A1 (en) | 1994-09-19 | 1996-03-28 | Eli Lilly And Company | Antiestrogenic benzothiophenyl compounds |
US5629425A (en) * | 1994-09-19 | 1997-05-13 | Eli Lilly And Company | Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene |
WO1998048792A1 (en) | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES |
WO2004029046A2 (en) | 2002-09-30 | 2004-04-08 | A/S Gea Farmaceutisk Fabrik | Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
WO2008000418A2 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | New method for salt preparation |
WO2008047105A1 (en) * | 2006-10-17 | 2008-04-24 | Cipla Limited | Crystalline form of benzothiophene compound and process for preparation thereof |
WO2011099942A1 (en) | 2010-02-09 | 2011-08-18 | Silverstone Pharma | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy |
-
2014
- 2014-03-05 WO PCT/GB2014/000081 patent/WO2014135834A1/en active Application Filing
- 2014-03-05 ZA ZA2014/01636A patent/ZA201401636B/en unknown
- 2014-03-05 IN IN665MU2013 patent/IN2013MU00665A/en unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4358593A (en) | 1981-04-03 | 1982-11-09 | Eli Lilly And Company | Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes |
US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
EP0584952A1 (en) | 1992-07-28 | 1994-03-02 | Eli Lilly And Company | Improvements in or relating to benzothiophenes |
WO1996009045A1 (en) | 1994-09-19 | 1996-03-28 | Eli Lilly And Company | Antiestrogenic benzothiophenyl compounds |
US5629425A (en) * | 1994-09-19 | 1997-05-13 | Eli Lilly And Company | Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene |
US20020173645A1 (en) | 1994-09-19 | 2002-11-21 | Luke Wayne Douglas | Non-solvated crystalline 6-hydroxy-2- (4-hydroxyphenyl) -3- [4- (2-piperidinoethoxy) benzoyl] benzo [b] thiophene hydrochloride |
WO1998048792A1 (en) | 1997-04-30 | 1998-11-05 | Eli Lilly And Company | A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES |
WO2004029046A2 (en) | 2002-09-30 | 2004-04-08 | A/S Gea Farmaceutisk Fabrik | Novel raloxifene acid addition salts and/or solvates thereof, improved method for purification of said raloxifene acid addition salts and/or solvates thereof and pharmaceutical compositions comprising these |
WO2008000418A2 (en) * | 2006-06-27 | 2008-01-03 | Sandoz Ag | New method for salt preparation |
WO2008047105A1 (en) * | 2006-10-17 | 2008-04-24 | Cipla Limited | Crystalline form of benzothiophene compound and process for preparation thereof |
WO2011099942A1 (en) | 2010-02-09 | 2011-08-18 | Silverstone Pharma | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10087191B2 (en) | 2015-06-16 | 2018-10-02 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
US10385060B2 (en) | 2015-06-16 | 2019-08-20 | Jiangsu Hengrui Medicine Co., Ltd. | Piperidine derivative and preparation method and pharmaceutical use thereof |
WO2017107754A1 (en) | 2015-12-22 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | Benzopiperidine derivative, preparation method thereof and medical use thereof |
US10398689B2 (en) | 2015-12-22 | 2019-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Benzopiperidine derivative, preparation method thereof and medical use thereof |
WO2021139756A1 (en) | 2020-01-10 | 2021-07-15 | 江苏恒瑞医药股份有限公司 | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine |
WO2023280309A1 (en) | 2021-07-09 | 2023-01-12 | 江苏恒瑞医药股份有限公司 | Salt types of tricyclic tetrahydro isoquinoline derivative |
Also Published As
Publication number | Publication date |
---|---|
ZA201401636B (en) | 2014-11-26 |
WO2014135834A8 (en) | 2014-11-27 |
IN2013MU00665A (en) | 2015-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100791872B1 (en) | Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them | |
JP5160892B2 (en) | A novel crystal form of (3-cyano-1H-indol-7-yl)-[4- (4-fluorophenethyl) piperazin-1-yl] methanone hydrochloride | |
US10807978B2 (en) | Process for preparation of palbociclib | |
US9012469B2 (en) | Crystalline naloxol-peg conjugate | |
JP2009035535A (en) | Crystalline polymorph of bazedoxifene acetate | |
EA025438B1 (en) | CRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(β-D-GLUCOPYRANOS-1-YL)BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTSCRYSTALLINE COMPLEX OF 1-CYANO-2-(4-CYCLOPROPYL-BENZYL)-4-(β-D-GLUCOPYRANOS-1-YL)BENZENE, METHODS FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS | |
JP2007532548A (en) | Crystalline polymorph of bazedoxifene acetate | |
ZA200605307B (en) | Polymorphic Forms of a Gabaa agonist | |
WO2008077871A1 (en) | Salts of tegaserod | |
EP2896609B1 (en) | Crystalline fingolimod citrate for the treatment of relapsing-remitting multiple sclerosis | |
WO2014135834A1 (en) | Oxalic acid addition salts and/or solvates of a selective estrogen receptor modulator | |
EP2247570B1 (en) | Novel salts of o-desmethyl-venlafaxine | |
EP3327012B1 (en) | Crystalline forms of bilastine and preparation methods thereof | |
WO2011007870A1 (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof | |
US11866420B2 (en) | Hydrochloride salt forms of a sulfonamide structured kinase inhibitor | |
US20220002302A1 (en) | Novel polymorphs of acalabrutinib, a bruton's tyrosine kinase inhibitor | |
JP6621761B2 (en) | Solid form of a pharmaceutically active compound | |
US10519150B2 (en) | Salts of morpholine derivative, crystal forms thereof, processes for producing the same, pharmaceutical compositions including the same, and use thereof | |
WO2007102074A2 (en) | Salts of quetiapine | |
CA3095922A1 (en) | Solid-state forms of abemaciclib, their use and preparation | |
AU2012283277B2 (en) | Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride | |
JP2019505509A (en) | Method for producing gefitinib crystal form A | |
US20060030711A1 (en) | Crystalline polymorph of pipindoxifene hydrochloride monohydrate | |
WO2011099942A1 (en) | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy | |
US20060030591A1 (en) | Crystalline polymorph of pipindoxifene hydrochloride monohydrate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14712702 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14712702 Country of ref document: EP Kind code of ref document: A1 |